TargetMol

CD24 Protein (Primary Amine Labeling), Human, Recombinant (mFc), Biotinylated

Product Code:
 
TAR-TMPK-00006
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPK-00006-100ug100ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPK-00006-1mg1mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPK-00006-500ug500ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. CD24 Protein (Primary Amine Labeling), Human, Recombinant (mFc), Biotinylated is expressed in HEK293 mammalian cells with C-mFc tag. The predicted molecular weight is 29.5 kDa and the accession number is P25063-1.
Molecular Weight:
29.5 kDa (predicted). Due to glycosylation, the protein migrates to 48-58 kDa based on Tris-Bis PAGE result.
Purity:
98%

References

1.Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.Nature. 2019 Jul 3doi: 10.1038/s41586-019-1456-0. 2.Sun F, et al. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design[J]. Oncotarget, 2017, 8(31):51238-51252.